Advanced Goal-Directed Fluid Management Using the Starling Device for Patients Undergoing Lung Resection Surgery: A National Randomized Trial

What this Trial Is About

Researchers are studying high-risk patients scheduled for lung resection surgery to see if using an individualized goal-directed fluid therapy (GDFT) guided by chest bioreactance improves outcomes within 30 days after surgery. Lung surgery poses challenges for monitoring stroke volume and cardiac output due to patient positioning and surgical conditions. Chest bioreactance offers a non-invasive, continuous way to monitor these heart functions, but its impact on patient outcomes has yet to be proven. During the study, patients will be randomly assigned to one of two groups. One group will receive fluid management guided by the Starling device using chest bioreactance during lung resection surgery. The other group will be managed according to standard care protocols as decided by the attending anesthesiologists. Because double blinding is not possible, an independent committee unaware of treatment assignments will review all clinical outcomes. Participants will be monitored for postoperative complications within 30 days after surgery using a classification system. Researchers will collect data on complications of severity class II or higher. The study includes adults aged 18 to 80 who are at high risk based on health scores and lung function. Patient consent and social health insurance affiliation are required. The total participation includes the surgery period and a 30-day postoperative follow-up to assess safety and complications.

Advanced Goal-Directed Impedancemetry Strategy for Lung Resection Surgery